查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2083270

腎神經阻斷市場商機、成長要素、產業趨勢分析及2026-2035年預測。

Renal Denervation Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球腎臟神經阻斷市場預計到 2025 年價值 5.5 億美元，預計到 2035 年將達到 64 億美元，年複合成長率為 27.8%。

腎臟去神經術市場-IMG1

這一顯著的成長軌跡使腎臟去神經治療市場躋身於更廣泛的心血管醫療設備業中成長最快的細分市場之列。市場擴張的主要驅動力是難治性高血壓治療方法的重大轉變，醫療專業人員擴大採用微創介入手術作為長期藥物治療的替代方案。人們對未控制高血壓及其相關健康風險的認知不斷提高，推動了醫生和醫療系統對腎臟去神經技術的接受度。持續的技術進步、不斷提升的臨床療效以及對長期治療效果日益增強的信心，進一步鞏固了市場發展勢頭。此外，關鍵醫療市場有利的監管政策和不斷擴大的商業化進程也促進了該技術的更廣泛應用。人口結構變化、文明病的增加以及慢性心血管危險因子盛行率的上升，持續擴大目標患者群體。腎臟去神經治療透過針對血壓調節的潛在機制，為那些無法透過傳統療法獲得最佳療效的患者提供了一種極具前景的治療選擇，從而支撐了預測期內市場的持續成長。

市場範圍
開始年份 2025
預測期 2026-2035
初始市場規模 5.5億美元
預測金額 64億美元
複合年成長率 27.8%

射頻技術領域佔49.4%的市場佔有率，預計到2035年將以29%的複合年成長率成長。其主導地位得益於早期商業化、豐富的臨床經驗以及醫療專業人員的廣泛認可。設備設計和治療效率的不斷提升推動了該技術的普及，而越來越多的臨床證據支持其安全性和有效性，進一步增強了醫生的信心。該技術能夠實現標靶治療，提供更全面的神經阻斷效果，從而鞏固了其強大的市場地位和未來的成長潛力。

預計到2025年，醫院通路將佔據63%的市場佔有率，並在2035年之前以29%的複合年成長率成長。該管道的主導地位反映了腎臟神經系統疾病的高度專業化，這種疾病需要先進的影像技術、專門的心血管護理基礎設施和全面的病患監測資源。大規模醫療機構和專業的循環系統中心憑藉其臨床專長、多學科護理團隊以及支持複雜介入治療的能力，繼續承擔相當一部分此類手術。

北美腎臟去神經術市場佔據38.8%的市場佔有率，預計到2035年將以26.9%的複合年成長率成長。該地區的成長主要得益於完善的醫療基礎設施、醫生認知度的提高、臨床實踐的普及以及有利的監管趨勢。美國是全部區域需求的最大貢獻者，這主要得益於對先進心血管療法的投資增加以及腎臟去神經術計畫在醫療機構中的整合。此外，醫療機構報銷流程的改進和財務透明度的提高也促進了該技術在全部區域更廣泛的應用和長期市場擴張。

目錄

第1章：調查方法

第2章執行摘要

第3章 行業洞察

  • 產業生態系分析
  • 影響產業的因素
    • 促進因素
      • 高血壓和抗藥性高血壓的盛行率增加
      • 人們對微創手術的認知不斷提高
      • 腎臟去神經支配技術的進展
      • 臨床試驗結果積極，證明了其有效性和安全性。
    • 產業潛在風險與挑戰
      • 對術式安全性和潛在併發症的擔憂
    • 機會
      • 整合利用人工智慧的精密技術
      • 擴大新興市場的准入
  • 成長潛力分析
  • 監理情勢
  • 價格趨勢分析
  • 技術與創新展望
    • 最新科技趨勢
    • 新興技術
  • 未來市場趨勢
  • 專利分析
  • 救贖方案
    • 全國適用政策（NCD）
  • 腎神經阻斷術例數
  • 難治性高血壓的流行病學和患者族群
  • 人工智慧和生成式人工智慧對市場的影響
  • 波特的分析
  • PESTLE分析

第4章 競爭情勢

  • 介紹
  • 企業矩陣分析
  • 企業市佔率分析
    • 世界
    • 北美洲
    • 歐洲
    • 亞太地區
    • LAMEA
  • 主要市場公司的競爭分析
  • 競爭定位矩陣
  • 主要進展
    • 併購
    • 夥伴關係和聯盟
    • 新產品發布
    • 業務拓展計劃

第5章 市場估計與預測：依技術分類，2022-2035年

  • 高頻法
  • 超音波法
  • 微注射法
  • 其他技術

第6章 市場估計與預測：依應用領域分類，2022-2035年

  • 高血壓
  • 慢性腎臟病
  • 其他用途

第7章 市場估計與預測：依最終用途分類，2022-2035年

  • 醫院
  • 門診手術中心
  • 專科診所

第8章 市場估計與預測：依地區分類，2022-2035年

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE

第9章：公司簡介

  • Abbott
  • ABLATIVE SOLUTIONS
  • Boston Scientific
  • Johnson &Johnson
  • Medtronic
  • Mercator MedSystems
  • Otsuka
  • Recor
  • SyMap Medical
  • Symple Surgical
  • TERUMO
  • VENUS MEDTECH
簡介目錄
Product Code: 12780

The Global Renal Denervation Market was valued at USD 550 million in 2025 and is estimated to grow at a CAGR of 27.8% to reach USD 6.4 billion by 2035.

Renal Denervation Market - IMG1

The remarkable growth trajectory places the renal denervation market among the fastest-growing segments within the broader cardiovascular device industry. Market expansion is being driven by a significant shift in the treatment approach for resistant hypertension, as healthcare providers increasingly adopt minimally invasive interventional procedures as an alternative to long-term medication intensification. Growing awareness of uncontrolled hypertension and its associated health risks is encouraging broader acceptance of renal denervation technologies among physicians and healthcare systems. Continuous technological advancements, expanding clinical validation, and increasing confidence in long-term treatment outcomes are further strengthening market momentum. In addition, favorable regulatory developments and expanding commercialization efforts across major healthcare markets are supporting wider adoption. The addressable patient population continues to increase due to demographic changes, rising rates of lifestyle-related health conditions, and the growing prevalence of chronic cardiovascular risk factors. By targeting the underlying mechanisms involved in blood pressure regulation, renal denervation offers a promising therapeutic option for patients who do not achieve optimal outcomes through conventional treatment approaches, supporting sustained market growth throughout the forecast period.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$550 Million
Forecast Value$6.4 Billion
CAGR27.8%

The radiofrequency-based technology segment held 49.4% share and is projected to grow at a CAGR of 29% through 2035. The segment's leadership position is attributed to its earlier commercialization, extensive clinical experience, and broad acceptance among healthcare professionals. Continued advancements in device design and procedural efficiency have strengthened adoption, while growing clinical evidence supporting safety and effectiveness continues to reinforce physician confidence. Technology enables targeted treatment delivery designed to achieve more comprehensive denervation outcomes, contributing to its strong market position and future growth potential.

The hospitals segment held a 63% share in 2025 and is expected to grow at a CAGR of 29% through 2035. The dominance of this segment reflects the specialized nature of renal denervation procedures, which require advanced imaging capabilities, dedicated cardiovascular care infrastructure, and comprehensive patient monitoring resources. High-volume healthcare facilities and specialized cardiovascular centers continue to perform many procedures due to their clinical expertise, multidisciplinary care teams, and ability to support complex interventional treatments.

North America Renal Denervation Market held 38.8% share and is projected to grow at a CAGR of 26.9% through 2035. The region's growth is supported by strong healthcare infrastructure, increasing physician awareness, expanding procedural adoption, and favorable regulatory developments. The United States represents the largest contributor to regional demand, benefiting from growing investment in advanced cardiovascular therapies and increasing integration of renal denervation programs within healthcare institutions. Improved reimbursement pathways and greater financial clarity for healthcare providers are also supporting wider adoption and long-term market expansion throughout the region.

Key companies operating in the global renal denervation market include Medtronic, Abbott, Boston Scientific, Johnson and Johnson, TERUMO, Recor Medical, Otsuka, VENUS MEDTECH, Mercator MedSystems, ABLATIVE SOLUTIONS, Symple Surgical, and SyMap Medical. Companies operating in the renal denervation market are implementing a variety of strategic initiatives to strengthen their competitive position and expand market presence. Significant investments in research and development remain a primary focus as manufacturers work to enhance procedural effectiveness, improve device performance, and simplify treatment delivery. Clinical trial expansion and evidence-generation programs continue to play a critical role in supporting physician adoption and demonstrating long-term therapeutic value. Strategic partnerships, collaborations with healthcare providers, and expansion of commercialization activities are helping companies increase market penetration and strengthen distribution networks. Many organizations are also investing in physician education programs, training initiatives, and awareness campaigns to accelerate procedural adoption.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Market definitions and scope
  • 1.2 Research approach
  • 1.3 Quality commitments
    • 1.3.1 GMI AI policy & data integrity commitment
      • 1.3.1.1 Source consistency protocol
  • 1.4 Research trail & confidence scoring
    • 1.4.1 Research trail components
    • 1.4.2 Scoring components
  • 1.5 Data collection
    • 1.5.1 Partial list of primary sources
  • 1.6 Data mining sources
    • 1.6.1 Paid sources
      • 1.6.1.1 Sources, by region
  • 1.7 Base estimates and calculations
    • 1.7.1 Base year calculation
  • 1.8 Forecast model
    • 1.8.1 Quantified market impact analysis
      • 1.8.1.1 Mathematical impact of growth parameters on forecast
  • 1.9 Research transparency addendum
    • 1.9.1 Source attribution framework
    • 1.9.2 Quality assurance metrics
    • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Technology trends
    • 2.2.3 Application trends
    • 2.2.4 End use trends
  • 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing Prevalence of Hypertension and Drug Resistant Hypertension
      • 3.2.1.2 Rising Awareness About Minimally Invasive Procedures
      • 3.2.1.3 Advancements in Renal Denervation Technologies
      • 3.2.1.4 Favorable Clinical Trial Outcomes Showcasing Efficacy and Safety
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Concerns About Procedural Safety and Potential Complications
    • 3.2.3 Opportunities
      • 3.2.3.1 Integration of AI-driven precision technologies
      • 3.2.3.2 Growing access in emerging markets
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pricing trend analysis
  • 3.6 Technology and innovation landscape (Driven by Primary Research)
    • 3.6.1 Current technological trends
    • 3.6.2 Emerging technologies
  • 3.7 Future market trends (Driven by Primary Research)
  • 3.8 Patent analysis
  • 3.9 Reimbursement scenario
    • 3.9.1 National Coverage Determinations(NCD) policy
  • 3.10 Renal denervation procedure volume
  • 3.11 Resistant hypertension epidemiology and patient population
  • 3.12 Impact of AI & Generative AI on the Market (Driven by Primary Research)
  • 3.13 Porter's analysis
  • 3.14 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis (Driven by Primary Research)
    • 4.3.1 Global
    • 4.3.2 North America
    • 4.3.3 Europe
    • 4.3.4 Asia Pacific
    • 4.3.5 LAMEA
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers & acquisitions
    • 4.6.2 Partnerships & collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Radiofrequency based
  • 5.3 Ultrasound based
  • 5.4 Micro-Infusion based
  • 5.5 Other technologies

Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Hypertension
  • 6.3 Chronic kidney disease
  • 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Ambulatory surgical centers
  • 7.4 Specialty clinics

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 MEA
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Abbott
  • 9.2 ABLATIVE SOLUTIONS
  • 9.3 Boston Scientific
  • 9.4 Johnson & Johnson
  • 9.5 Medtronic
  • 9.6 Mercator MedSystems
  • 9.7 Otsuka
  • 9.8 Recor
  • 9.9 SyMap Medical
  • 9.10 Symple Surgical
  • 9.11 TERUMO
  • 9.12 VENUS MEDTECH